The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IDYA | +74.53% | +44.18% | +7.58% | +196% |
| S&P | +20.12% | +68.19% | +10.95% | +135% |
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $10.88M | 55.4% |
| Gross Profit | $9.68M | 52.3% |
| Gross Margin | 88.99% | -1.8% |
| Market Cap | $3.03B | 36.4% |
| Market Cap / Employee | $20.90M | 0.0% |
| Employees | 145 | 10.7% |
| Net Income | -$83,273.00K | 36.1% |
| EBITDA | -$93,373.00K | 34.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $112.83M | 33.7% |
| Accounts Receivable | $3.00K | 0.0% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $27.58M | 46.1% |
| Short Term Debt | $339.00K | 13.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -10.18% | 20.8% |
| Return On Invested Capital | -18.72% | 2.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$90,829.00K | 26.0% |
| Operating Free Cash Flow | -$90,496.00K | 25.6% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.34 | 1.80 | 2.48 | 2.78 | 47.60% |
| Price to Sales | 206.75 | 265.67 | 11.36 | 14.00 | -95.63% |
| Price to Tangible Book Value | 1.34 | 1.80 | 2.48 | 2.78 | 47.60% |
| Enterprise Value to EBITDA | -9.38 | -13.89 | 15.35 | -26.25 | 137.25% |
| Return on Equity | -31.3% | -35.1% | -14.1% | -10.9% | -66.57% |
| Total Debt | $25.97M | $26.60M | $27.25M | $27.91M | 45.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
